Vertex and AbCellera Partner to Develop Next-Generation Multispecific T-cell Engagers
Vertex Pharmaceuticals (VRTX), a leader in Cystic Fibrosis (CF) treatment with over $10 billion in annual revenue, is diversifying its portfolio. To overcome its reliance on a single disease area, Vertex acquired Alpine Immune Sciences for $4.8 billion in May 2024, gaining access to the late-stage povetacicept. In July 2026, it acquired Crinetics (CRNX) for $10 billion. The partnership with AbCellera (ABCL) represents a strategic decision to leverage platform technology and expand its pipeline in Autoimmune Diseases, starting from early discovery.
The core of this collaboration is the discovery of next-generation Multispecific T-cell Engager (TCE) candidates targeting autoimmune diseases, utilizing AbCellera's antibody discovery platform. TCEs induce the patient's T-cells to selectively kill pathogenic B-cells, offering a novel mechanism. Existing approved therapies like Roche's Columvi (glofitamab) and Pfizer's Elrexfio (elranatamab) are primarily developed for hematological malignancies. The companies aim to extend this mechanism to chronic autoimmune diseases, addressing the unmet medical need for safe and deep B-cell depletion.
This collaboration model, where big pharma partners with platform-based biotech companies to reduce R&D risk, is becoming increasingly common. AbCellera secured an upfront payment of $28 million, validating its platform. AbCellera will lead candidate discovery and early development, while Vertex will fund all R&D costs and retain exclusive commercialization rights. AbCellera will also receive milestone payments and tiered royalties based on future pre-clinical, clinical, regulatory, and commercial success, ensuring sustainable growth.
The global autoimmune disease market is a $100 billion market, and the paradigm is shifting towards precision medicine that targets specific cells. TCEs, which can be mass-produced as off-the-shelf products, offer significant potential in terms of cost and convenience compared to CAR-T therapies. UCB's acquisition of Candid Therapeutics for $2.2 billion in May 2026 to secure assets like cizutamig, as well as deals made by Merck (MRK) and Sanofi (SNY), demonstrate the intense competition to secure B-cell-targeting TCEs. Vertex's entry into this space can be seen as a move to gain market leadership in the evolving next-generation immunotherapy landscape.
Vertex (VRTX), with over $10 billion in annual Cystic Fibrosis revenue, is entering the $100 billion autoimmune disease market by proactively securing next-generation Multispecific T-cell Engagers (TCEs), establishing a foundation for long-term growth. This deal is significant in the competitive landscape where UCB acquired Candid Therapeutics for $2.2 billion to secure B-cell-targeting pipelines like cizutamig, as Vertex secures early-stage platform technology with an efficient upfront payment of $28 million. In the short term, this will likely increase market recognition of AbCellera's (ABCL) antibody discovery and TCE engineering platforms and accelerate subsequent pre-clinical development. In the long term, the successful translation of B-cell-targeting therapies, already approved for hematological malignancies like Columvi, into off-the-shelf therapies for autoimmune diseases is expected to accelerate clinical development and commercialization.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/abcellera-vertex-partnership-next-gen-t-cell-engagers/826471/